8-KAcquisitions & DispositionsExhibits & Filings

Merck & Co., Inc. 8-K Report, Acquisition Completed (Oct 2, 2014)

Filed October 2, 2014For Securities:MRK

Summary

Merck & Co., Inc. announced the completion of the sale of its Merck Consumer Care (MCC) business to Bayer AG on October 1, 2014. This strategic divestiture, for which a Stock and Asset Purchase Agreement was signed on May 5, 2014, includes the global trademark and prescription rights for well-known brands like Claritin and Afrin. The transaction generated $14.2 billion in gross proceeds, resulting in approximately $9 billion in after-tax proceeds, subject to customary closing adjustments and potential contingent amounts related to the transfer of manufacturing sites and regulatory approvals in specific regions.

Key Highlights

  • 1Merck completed the sale of its Consumer Care business to Bayer AG on October 1, 2014.
  • 2The sale includes global trademark and prescription rights for brands such as Claritin and Afrin.
  • 3The transaction's gross value was $14.2 billion.
  • 4Merck expects to receive approximately $9 billion in after-tax proceeds.
  • 5Proceeds are subject to customary closing adjustments and potential contingent payments.
  • 6The company has filed a press release (Exhibit 99.1) detailing the disposition.
  • 7Unaudited Pro Forma Financial Information related to this transaction is also available as Exhibit 99.2.

Frequently Asked Questions

This 8-K filing primarily announces the completion of Merck's sale of its Consumer Care business to Bayer AG, providing key financial details of the transaction.

The sale included the global trademark and prescription rights for brands such as Claritin and Afrin, among other over-the-counter products.

Merck expects to receive approximately $9 billion in after-tax proceeds from the sale. This amount is after considering the gross proceeds of $14.2 billion and is subject to customary closing adjustments and certain contingent payments.

More detailed information can be found in the exhibits attached to this 8-K filing: Exhibit 99.1 contains the press release announcing the disposition, and Exhibit 99.2 provides Merck's Unaudited Pro Forma Financial Information related to the sale.